Skandinaviska Enskilda Banken Ab (Publ) Denali Therapeutics Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 43,245 shares of DNLI stock, worth $624,025. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,245
Previous 43,245
-0.0%
Holding current value
$624,025
Previous $1.26 Million
30.02%
% of portfolio
0.0%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding DNLI
# of Institutions
240Shares Held
121MCall Options Held
80KPut Options Held
36.8K-
Black Rock Inc. New York, NY13.2MShares$190 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$178 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$173 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA9.85MShares$142 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.48MShares$79 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $1.94B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...